Nuveen Asset Management, LLC Tyme Technologies, Inc. Transaction History

Nuveen Asset Management, LLC

$334 Billion
Q2 2024

Shares

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2021 Aug 16, 2021	SELL	$1.14 - $1.87 $485,863 - $796,986	-426,196 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$1.34 - $3.53 $63,542 - $167,392	47,420 Added 12.52%	426,196 $758,000
Q4 2020 Feb 16, 2021	BUY	$0.87 - $1.26 $10,192 - $14,762	11,716 Added 3.19%	378,776 $462,000
Q3 2020 Nov 16, 2020	BUY	$0.93 - $1.35 $2,782 - $4,039	2,992 Added 0.82%	367,060 $360,000
Q2 2020 Aug 14, 2020	BUY	$0.97 - $1.7 $109,927 - $192,655	113,327 Added 45.2%	364,068 $484,000
Q1 2020 May 14, 2020	BUY	$0.9 - $1.95 $34,075 - $73,830	37,862 Added 17.79%	250,741 $275,000
Q4 2019 Feb 14, 2020	SELL	$1.0 - $1.49 $41,685 - $62,110	-41,685 Reduced 16.38%	212,879 $298,000
Q3 2019 Nov 14, 2019	SELL	$0.97 - $1.77 $65,214 - $118,998	-67,231 Reduced 20.89%	254,564 $302,000
Q2 2019 Aug 15, 2019	BUY	$0.96 - $1.89 $308,923 - $608,192	321,795 New	321,795 $392,000

About TYME TECHNOLOGIES, INC.

Ticker TYME
Exchange NASDAQ
Shares Outstandng 172,207,008
Description
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...

More about TYME

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.